MAPT and supranuclear palsy, progressive, 1: In a PSP phase II trial, gosuranemab was effective in reducing CSF N-terminal CSF; however, 3 patients who went to autopsy showed no change in intracellular tau pathology, although there was evidence of tau accumulation in the lysosomes of perivascular astrocytes [89,90].